Search research publications and outputs

  1. CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations

    Khanna, A., Rane, J. K., Kivinummi, K. K., Urbanucci, A., Helenius, M. A., Tolonen, T. T., Saramäki, O. R., Latonen, L., Manni, V., Pimanda, J. E., Maitland, N. J., Westermarck, J. & Visakorpi, T., 19 Apr 2015

    Article in Oncotarget

  2. Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy

    Santer, F. R., Erb, H. H. H., Oh, S. J., Handle, F., Feiersinger, G. E., Luef, B., Bu, H., Schäfer, G., Ploner, C., Egger, M., Rane, J. K., Maitland, N. J., Klocker, H., Eder, I. E. & Culig, Z., 20 Mar 2015

    Article in Oncotarget

  3. miR-25 modulates invasiveness and dissemination of human prostate cancer cells via regulation of αv- and α6 integrin expression

    Zoni, E., van der Horst, G., van de Merbel, A. F., Chen, L., Rane, J. K., Pelger, R. C. M., Collins, A. T., Visakorpi, T., Snaar-Jagalska, B. E., Maitland, N. J. & van der Pluijm, G., 1 Jun 2015

    Article in Cancer research